140 delegates from the European Active Pharmaceutical Ingredient and intermediate industry
and a range of national and European regulatory authorities attended the inaugural GMP
Conference on Active Pharmaceutical Ingredients in Brussels from Wednesday 9th September
to Friday 11th September. The Conference was run by 'The Active Pharmaceutical Ingredients
Committee (APIC) of CEFIC (The European Chemical Industries Council) in association with
Concept Heidelberg.
Conference delegates discussed a number of breaking issues currently effecting the
European actives industry including
- The latest draft of the EU Directive on starting
materials-presented by Beatrice Hughes, European Commission DG III
- The Internationally Harmonised Guide on GMP for Active
Pharmaceutical Ingredients - presented and discussed by Bernhard Scherz (IKS) and Gordon
Munro (MCA)
- Ph. Eur. Certificates of Suitability and European Drug Master Files
- presented by Agnes Artiges, European Pharmacopoeia
- The current status of the Mutual Recognition Agreement (MRA) with
the U.S.A. and Canada presented by Matt Moran, vice-chairman CEFIC-APIC.
The delegates who came from over 20 countries, inside and outside
Europe learnt of the rapidly changing regulatory environment as it effects GMPs within the
Actives industry. The importance of Europe possessing an inspection regime which will
complement and facilitate the successful completion of the MRA with the U.S.A. was
emphasized. Companies were advised of the need to be ready and prepared to adhere to the
proposed EU Directive on Starting Materials and the supporting ICH Guideline on GMPs for
actives.
Speaking after the Conference APIC Chairman, Dr. Henri Leblanc
(Rhodia-Chimie) said:
'European actives industry, through CEFIC-APIC is highly
supportive of the current ICH process aimed at producing a global GMP guide for the
industry. I am optimistic that the consences being sought on this by the ICH partners will
produce a guide of great benefit to the industry'.
He went on to say:
'When consens is achieved it is vital that a level playing field in GMP is applied inside
and outside the trading zone covered by the MRA agreement. The European Actives industry
remains commited to high quality and protection of the ultimate consumer, the patient.
However with quality comes lost and the European Industry would be disappointed if sub
standard materials are imported into this area. Disadvantaging the European industry area
ultimately jeoparding the patient.'
Dr. Leblanc called for regulatory agencies within the ICH area to be extra vigilant in
this regard. Gordon Munro, MCA informed the Conference delegates that the next ICH meeting
on the global GMP Guide was scheduled to take place in January of 1999. It now seems
likely that the transition phase of the MRA with the USA will commence in November of 1998
at the earliest.
For further information contact
Matt Moran, Vice Chairman CEFIC APIC, phone + 3 53 / 6 05 15 67
Henri Leblanc, Chairman CEFIC APIC, phone + 3 34 / 72 78 15 76
Loic Le Doré, Secretariat CEFIC APIC, phone + 3 22 / 67 67 21 11
Karl Metzger, CONCEPT, phone + 49 6221 / 84 44-0